Audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare muscle diseases through the application of adeno-associated virus (AAV) gene therapy technology.
Acumen is revolutionizing the diagnosis and treatment of autism and other disorders through smartphone-enabled digital behavior evaluation, improving outcomes for patients and simplifying care for specialists.
Biotie is a specialized drug development company focused on the development of drugs for neurodegenerative and psychiatric disorders and inflammatory diseases
CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough therapies addressing unmet medical needs.
Flap is a non operating company with rights to future milestones and royalties from GlaxoSmithKline related to the advancement of Amira’s FLAP inhibitor.
Fluidigm has developed the biological and chemical equivalent of the integrated circuit called Integrated Fluidic Circuits (IFC’s). IFC’s incorporate tens of thousands of miniature channels, pumps and valves.
GenSight is a leading company in gene therapy specialized in prevention of loss of vision and restoration of sight.
Groove Biopharma develops therapeutics using Minor Groove Binder Technology (MGB) to affect cellular processes involving microRNAs.
Immune Design uses breakthrough technology to develop new vaccines for the prevention and treatment of infectious disease, based on a novel understanding of the role of dendritic cells in the immue system.
Inception 1 is translating biological insights into novel, first-in-class, small molecule drugs to treat diseases of aging.
Inception 2 is focused on Oncology. The company is translating biological insights into novel, first-in-class small molecule drugs for CLL and other oncology indications spanning both liquid and solid tumors.
Inception 3 is focused on the discovery of therapeutics for sensorineural hearing loss. The company has entered into a partnership with Roche with a pre-negotiated acquisition at IND.
Inception Genomics is making use of significant advances in the field of gene editing and focused on translating the CRISPR-Cas9 technology in truly transformational therapeutics for common and rare genetic diseases.
Inception IBD is focused on translating academic discoveries in the field of IBD into first-in-class small molecule drugs.
Novira Therapeutics is an antiviral drug discovery company that is focused on the discovery and development of first-in-class antiviral therapeutics for the treatment of chronic HBV infections.
OpGen is developing a molecular biology system to automate rapid (2-hour) identification of infection-causing bacteria for deployment in the hospital microbiology lab.
Panmira focuses on clinical development of CRTH2 program for multiple allergic and inflammatory conditions.
PhaseRx is developing a novel approach to intracellular delivery of macromolecules.
Quanticel is a pharmaceutical company focused on the development of improved cancer therapeutics and their companion diagnostics.
RuiYi is a drug discovery and development company focused on first-in-class antibodies targeting G protein coupled receptors (GPCRs).
Theraclone Sciences, Inc. is focused on developing novel human therapeutic antibodies for the treatment of infectious diseases.
VLST Corp. has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases.
5AM Ventures is a seed-stage fund focused on creating and building biotech companies.